SPARC Induces E-Cadherin Repression and Enhances Cell Migration Through Integrin αvβ3 and the Transcription Factor ZEB1 in Prostate Cancer Cells
Overview
Chemistry
Molecular Biology
Authors
Affiliations
Secreted protein acidic and rich in cysteine (SPARC), or osteonectin, is a matricellular protein that modulates interactions between cells and their microenvironment. SPARC is expressed during extracellular matrix remodeling and is abundant in bone marrow and high-grade prostate cancer (PCa). In PCa, SPARC induces changes associated with epithelial-mesenchymal transition (EMT), enhancing migration and invasion and increasing the expression of EMT transcriptional factor Zinc finger E-box-binding homeobox 1 (ZEB1), but not Zinc finger protein SNAI1 (Snail) or Zinc finger protein SNAI2 (Slug). It is unknown whether the SPARC-induced downregulation of E-cadherin in PCa cells depends on ZEB1. Several integrins are mediators of SPARC effects in cancer cells. Because integrin signaling can induce EMT programs, we hypothesize that SPARC induces E-cadherin repression through the activation of integrins and ZEB1. Through stable knockdown and the overexpression of SPARC in PCa cells, we demonstrate that SPARC downregulates E-cadherin and increases vimentin, ZEB1, and integrin β3 expression. Knocking down SPARC in PCa cells decreases the tyrosine-925 phosphorylation of FAK and impairs focal adhesion formation. Blocking integrin αvβ3 and silencing ZEB1 revert both the SPARC-induced downregulation of E-cadherin and cell migration enhancement. We conclude that SPARC induces E-cadherin repression and enhances PCa cell migration through the integrin αvβ3/ZEB1 signaling pathway.
Beyaert S, Loriot A, Machiels J, Schmitz S Int J Mol Sci. 2025; 26(5).
PMID: 40076457 PMC: 11898532. DOI: 10.3390/ijms26051830.
Prostate Cancer Bone Metastasis: Molecular Mechanisms of Tumor and Bone Microenvironment.
Jiang H Cancer Manag Res. 2025; 17:219-237.
PMID: 39912095 PMC: 11796448. DOI: 10.2147/CMAR.S495169.
Popeda M, Kowalski K, Wenta T, Beznoussenko G, Rychlowski M, Mironov A Exp Mol Med. 2024; 56(9):2016-2032.
PMID: 39218980 PMC: 11446916. DOI: 10.1038/s12276-024-01308-w.
Yao W, Wang Z, Ma H, Lin Y, Liu X, Li P Heliyon. 2024; 10(14):e34269.
PMID: 39108889 PMC: 11301171. DOI: 10.1016/j.heliyon.2024.e34269.
Ashrafizadeh M, Dai J, Torabian P, Nabavi N, Aref A, Aljabali A Cell Mol Life Sci. 2024; 81(1):214.
PMID: 38733529 PMC: 11088560. DOI: 10.1007/s00018-024-05236-w.